Something deeply alarming was said in Barcelona on 22 April 2026, and it deserves far more attention than it has received. At the Reuters Pharma Europe conference, Emer Cooke, the Executive Director of the European Medicines Agency the body responsible for approving and supervising medicines across the entire European Union delivered a warning that should concern every patient, every carer, and every policymaker on this continent. Since May of the previous year, when the United States introduced a new drug pricing policy known as Most Favoured Nation pricing, the number of drug launches in Europe had fallen by more than one-third. More than one-third. In a single year. "We're at a very critical point at the moment," Cooke said. The language was careful, measured, and institutional and precisely because of that, the alarm it carried was all the more striking. Europe's drug access crisis, long building in the background of healthcare policy debates, has now broken fully into the open.
To understand how Europe arrived at this moment, you have to trace a set of converging pressures that have been accumulating for well over a decade structural, economic, geopolitical, and regulatory each of which individually might have been manageable, but which together have created a situation that public health experts are describing with unusual urgency. The starting point is a simple and devastating trend. In 1990, approximately 49 percent of global pharmaceutical research and development took place in Europe and 33 percent in the United States. By 2025, only 26 percent took place in Europe, while 55 percent was being conducted in the US. That is not a marginal statistical shift. It represents the wholesale migration of the global pharmaceutical innovation engine away from the continent that once led it a migration driven by pricing policy, regulatory pace, and the cold commercial logic of where capital generates its best return.
The consequences of that migration are now arriving at hospital bedsides, pharmacy counters, and oncology clinics across the UK and EU. EU countries ran critically short of 136 medicines between January 2022 and October 2024, with 2023 and 2024 recording the highest levels of medicine shortages reported across the European Union. These were not obscure or niche compounds. The shortages affected antibiotics, insulin, cancer treatments, and vaccines the foundational medicines that modern healthcare systems depend on to function. The European Commission's critical medicines list a register of drugs whose shortage would cause serious harm to patients currently contains more than 270 active substances, and the list continues to grow. The number of reported drug shortage notifications escalated from a few dozen in 2011 to more than 1,500 products in 2023, a trajectory that no healthcare system on earth was designed to absorb without harm.
The human cost of that trajectory is not abstract. A 2025 survey by the European Association of Hospital Pharmacists found that medicines shortages affect patient care in 89 percent of hospitals and pharmacy operations in 79 percent, with all respondent pharmacists having experienced shortages of critical medicines at least one to three times in 2024 alone. The consequences reported by frontline clinical staff are a catalogue of harm: delays in care or therapy, cancellation of treatment, and patients receiving suboptimal alternatives because their prescribed medicine was simply not available. In settings like oncology or epilepsy where the right drug at the right time is not a matter of preference but of survival these are not inconveniences. They are medical crises playing out in individual lives, largely invisible to the broader public because they unfold one patient at a time, inside clinical spaces, without the drama of an emergency declaration.
The causes of Europe's medicine shortage are multiple and interconnected, and understanding them is essential to understanding why the problem is so resistant to easy fixes. More than 50 percent of reported drug shortfalls are caused by manufacturing issues, including a lack of production capacity in the face of unexpected demand surges, commercial decisions, and vulnerabilities in the supply of active pharmaceutical ingredients especially when those ingredients come from limited suppliers based outside the EU. The stark reality is that the majority of the raw chemical ingredients used to manufacture medicines sold in Europe are produced in India and China. That geographic concentration creates a supply chain fragility that global events a pandemic, a geopolitical conflict, a manufacturing contamination incident can rupture almost instantly. The fact that most medicines are authorised nationally, and that those authorised for the entire EU are not made available in all member states by manufacturers, further increases the risk of bottlenecks across the continent.
The pricing dimension of this crisis is where things become genuinely politically charged, and where the question of why medicines are expensive in Europe or rather, why medicines are becoming unavailable in Europe demands a more sophisticated answer than most public debate provides. The paradox at the heart of the European pharmaceutical market is that governments have, for decades, used their power as large collective buyers to negotiate lower drug prices through national health systems. Those negotiations conducted country by country, each using the prices agreed elsewhere as a reference point in a system called external price referencing have successfully kept medicine costs lower in Europe than in the United States. But that success has a shadow. Prices of generic medicines have not been raised for more than 20 years in countries like Germany. That might sound like a consumer triumph, but it has progressively made the European market less commercially viable for manufacturers, eroding the investment case for maintaining production lines, launching new products, and conducting clinical trials on European soil.
Now, a new and destabilising force has entered this already fragile system. President Trump's Most Favoured Nation pricing policy which aims to ensure the United States pays no more for medicines than any other country in the world is restructuring global pharmaceutical commerce in ways that Europe is only beginning to fully absorb. Europe is the second-largest global pharmaceutical market, but leading industry figures are increasingly directing research and investment toward the US and China, where the regulatory framework is considered easier to navigate and prices are potentially higher because universal healthcare systems across Europe give governments leverage in price negotiations that limits manufacturer returns. The MFN policy, intended to lower US drug costs, is producing a counterintuitive consequence: it is raising pressure on European prices upward, because pharmaceutical companies facing reduced US margins are now threatening to withdraw products from European markets that do not offer higher reimbursement. The pharmaceutical industry has been openly signalling that it may withhold drugs from markets that will not meet their demands for higher prices framing this, in corporate language, as a failure to "properly value innovation." (Statnews)
The regulatory architecture through which new medicines reach European patients adds another layer of structural disadvantage. Looking at all 545 new active substances approved in the US, EU, or Japan between 2014 and 2022, the United States had the highest approval rate at 89 percent, while the European Medicines Agency's median approval time stood at around 423 days in 2019 against its official target of 210 days. (EFPIA) That gap between target and reality, and between European and American regulatory speed means that patients in the UK and across EU member states are routinely waiting longer for access to medicines that have already been approved and are being used by patients in the United States. For a patient with an aggressive cancer or a rare progressive disease, twelve extra months waiting for regulatory clearance is not a policy statistic. It is a material dimension of their prognosis.
The EU is not passive in the face of this crisis, and several significant institutional responses have been set in motion. The European Shortages Monitoring Platform, launched in November 2024 for routine reporting and designed to become fully operational in February 2025, is intended to centralise and automate data collection on medicine availability, offering real-time supply and demand information to alert regulators to potential unmet needs before shortages become acute. (Euronews) Previously, drug shortage data was chronically underreported and delayed, partly because manufacturers were reluctant to share commercially sensitive supply chain information with regulators. The new platform attempts to close that information gap by creating a standardised, mandatory reporting architecture across the EU. In March 2025, the European Commission published its proposal for a Critical Medicines Act, outlining key actions including incentivising strategic manufacturing projects, rethinking procurement models, and fostering international strategic partnerships to strengthen supply chain resilience. (EAHP) The Act would also allow EU member states to pool their purchasing power a collective bargaining mechanism that could, in theory, make the European market more attractive to manufacturers by offering more predictable, larger-scale demand guarantees.
But the pace at which these reforms are moving sits in uncomfortable tension with the urgency of the problem. Europe's pharmaceutical reform package has taken seven years to negotiate and updates rules that are 25 years old not fast enough to respond to rapid global changes, according to health economists. The Critical Medicines Act, however welcome, will not resolve a manufacturing pipeline crisis or reverse a decade of R&D migration within the timeframes that matter to the patients currently being told that their treatment has been delayed or their prescription cannot be filled. A trade deal between the US and the EU, which has yet to be ratified by the European Parliament, includes 15 percent tariffs on branded medicines that could cost the pharmaceutical sector up to $19 billion a cost that will ultimately be absorbed either by manufacturers scaling back European operations further, or by patients and health systems paying more for the medicines that do remain available.
What makes this crisis particularly difficult to communicate to the public is that it is slow-moving, structurally embedded, and distributed across millions of individual encounters between patients and healthcare systems rather than erupting in the form of a single dramatic event. A person with Type 2 diabetes whose insulin formulation is temporarily unavailable, a child with epilepsy whose seizure medication requires substitution because the original brand is out of stock, a cancer patient told that a recently approved immunotherapy is not yet reimbursed in their country each of these is an instance of the same systemic failure, separated by condition, country, and circumstance, but united by the same underlying dynamic. Drug shortages can harm patients by hindering access to necessary therapies, increasing the risk of mortality, and raising the risk of adverse events due to inadequate alternative treatments, with the WHO classifying drug shortages as a complex worldwide challenge requiring coordinated action by member states. (The Lancet) Europe is discovering, slowly and painfully, that decades of competitive drug pricing pursued with the best of intentions for public finances and patient access have produced a pharmaceutical landscape in which the medicines people need are increasingly either unavailable, delayed, or subject to geopolitical pressures entirely outside patients' control.
Comments
Post a Comment